Hope for Parkinson’s disease symptoms is found in late-stage drug study
Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...
AbbVie's Parkinson's disease drug meets main goal in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease met the main goal in a late-stage study, the drugmaker said on ...
AbbVie's Parkinson's disease drug improves patient mobility in late-stage study
AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...
This Drugmaker's (ABBV) Parkinson's Medication Just Cleared A Key Hurdle – Is It Primed ...
Meta-Description: Drugmaker AbbVie could be set up for a big year in 2025 after completing another successful clinical trial ...
AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study
AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational ...
PharmTech4 天
European Biotechs Unlocking Parkinson’s Disease
Centogene NV and ROPAD consortium publish data from a landmark study identifying genetic variants that may respond to ...
Reuters8 天
In paraquat lawsuits, an expert gets bumped (again)
The late November decision by a judge in Contra Costa County follows an earlier order ... science-based review of regulatory ...
AbbVie's Tavapadon Hits Key Goals in Third Phase 3 Parkinson's Study
AbbVie, which in September reported that tavapadon had met the primary and secondary endpoints in a Phase 3 fixed-dose monotherapy trial, said it is on track to file for Food & Drug Administration ...